201 related articles for article (PubMed ID: 8529568)
1. [Glutamatergic hypothesis of schizophrenia: psychoses induced by phencyclidine and cortical-subcortical imbalance].
Krebs MO
Encephale; 1995; 21(5):581-8. PubMed ID: 8529568
[TBL] [Abstract][Full Text] [Related]
2. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
3. A review of NMDA receptors and the phencyclidine model of schizophrenia.
Thornberg SA; Saklad SR
Pharmacotherapy; 1996; 16(1):82-93. PubMed ID: 8700797
[TBL] [Abstract][Full Text] [Related]
4. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
5. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
Large CH
J Psychopharmacol; 2007 May; 21(3):283-301. PubMed ID: 17591656
[TBL] [Abstract][Full Text] [Related]
6. [Neuropsychopharmacological study on an animal model for negative symptom of schizophrenia induced by repeated phencyclidine treatment].
Noda Y; Nabeshima T
Yakugaku Zasshi; 2000 Aug; 120(8):677-82. PubMed ID: 10946617
[TBL] [Abstract][Full Text] [Related]
7. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia.
Javitt DC
Hillside J Clin Psychiatry; 1987; 9(1):12-35. PubMed ID: 2820854
[TBL] [Abstract][Full Text] [Related]
8. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment.
Mouri A; Noda Y; Enomoto T; Nabeshima T
Neurochem Int; 2007; 51(2-4):173-84. PubMed ID: 17669558
[TBL] [Abstract][Full Text] [Related]
9. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors.
Bubeníková-Valesová V; Horácek J; Vrajová M; Höschl C
Neurosci Biobehav Rev; 2008 Jul; 32(5):1014-23. PubMed ID: 18471877
[TBL] [Abstract][Full Text] [Related]
10. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
Nabeshima T; Mouri A; Murai R; Noda Y
Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
[TBL] [Abstract][Full Text] [Related]
11. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
[TBL] [Abstract][Full Text] [Related]
12. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia.
Jentsch JD; Roth RH
Neuropsychopharmacology; 1999 Mar; 20(3):201-25. PubMed ID: 10063482
[TBL] [Abstract][Full Text] [Related]
13. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
Hashimoto K; Iyo M
Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
[TBL] [Abstract][Full Text] [Related]
14. Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: implications for schizophrenia.
Zavitsanou K; Nguyen V; Newell K; Ballantyne P; Huang XF
J Chem Neuroanat; 2008 Oct; 36(2):71-6. PubMed ID: 18640263
[TBL] [Abstract][Full Text] [Related]
15. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function.
Krystal JH; Perry EB; Gueorguieva R; Belger A; Madonick SH; Abi-Dargham A; Cooper TB; Macdougall L; Abi-Saab W; D'Souza DC
Arch Gen Psychiatry; 2005 Sep; 62(9):985-94. PubMed ID: 16143730
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of locomotor activity by chronic phencyclidine is associated with an increase in striatal NMDA receptor function and an upregulation of the NR1 receptor subunit.
Hanania T; Hillman GR; Johnson KM
Synapse; 1999 Mar; 31(3):229-39. PubMed ID: 10029241
[TBL] [Abstract][Full Text] [Related]
17. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis.
Enomoto T; Noda Y; Nabeshima T
Methods Find Exp Clin Pharmacol; 2007 May; 29(4):291-301. PubMed ID: 17609743
[TBL] [Abstract][Full Text] [Related]
18. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
Pietraszek M
Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
[TBL] [Abstract][Full Text] [Related]
19. Involvement of a dysfunctional dopamine-D1/N-methyl-d-aspartate-NR1 and Ca2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine.
Mouri A; Noda Y; Noda A; Nakamura T; Tokura T; Yura Y; Nitta A; Furukawa H; Nabeshima T
Mol Pharmacol; 2007 Jun; 71(6):1598-609. PubMed ID: 17344353
[TBL] [Abstract][Full Text] [Related]
20. Neonatal phencyclidine treatment selectively attenuates mesolimbic dopamine function in adult rats as revealed by methamphetamine-induced behavior and c-fos mRNA expression in the brain.
Semba J; Tanaka N; Wakuta M; Suhara T
Synapse; 2001 Apr; 40(1):11-8. PubMed ID: 11170217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
